SCHEMBL64109

SCHEMBL64109

Nc1nc(=O)[nH]cc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18259564 0.89 MAPK1 (0.35)
SCHEMBL15972345 0.80 MMP2 (0.53)
SCHEMBL5143009 0.76
SCHEMBL1765946 0.73
SCHEMBL1231792 0.73 ATAD2 (0.37)
SCHEMBL11158635 0.73
SCHEMBL30609151 0.73
SCHEMBL22008 0.73
SCHEMBL8194730 0.73
Flucytosine SCHEMBL24063 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3410 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630827-B2 Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies ROGCON, INC. (US) 2026-05-19 US claimed
CN-122029176-A Containing a plurality of oligonucleotides modified oligonucleotides 阿达尔克斯制药有限公司 2026-05-12 CN claimed
CN-122028913-A Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions 阿达尔克斯制药有限公司 2026-05-12 CN claimed
CN-122029177-A Oligonucleotides containing multiple ligands and/or lipids 阿达尔克斯制药有限公司 2026-05-12 CN claimed
EP-4638717-A2 ENGINEERED RNA LIGASE VARIANTS Codexis, Inc. (US) 2025-10-29 EP claimed
WO-2025199647-A1 C4'-MODIFIED NUCLEOSIDE ANALOGUES AND SYNTHETIC METHODS THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2025-10-02 WO claimed
US-20250179503-A1 METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS PRAXIS PREC MEDICINES INC (US) 2025-06-05 US claimed
WO-2025111430-A1 CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL PRIME MEDICINE, INC. (US) 2025-05-30 WO claimed
WO-2025111452-A2 CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs PRIME MEDICINE, INC. (US) 2025-05-30 WO claimed
US-20250146073-A1 METHODS FOR THE TREATMENT OF SCN2A-RELATED DISORDERS PRAXIS PREC MEDICINES INC (US) 2025-05-08 US claimed
EP-0736105-A1 SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX NeXstar Pharmaceuticals, Inc. (US) 1996-10-09 EP claimed
EP-0540686-B1 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES US COMMERCE (US) 1995-08-30 EP claimed
WO-1995008003-A1 SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX UNIVERSITY RESEARCH CORPORATION (US) 1995-03-23 WO claimed
EP-0540686-A4 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES US COMMERCE (US) 1993-05-26 EP claimed
EP-0540686-A1 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. US COMMERCE (US) 1993-05-12 EP claimed
EP-0525106-A4 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS 1993-04-21 EP claimed
EP-0525106-A1 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS SOUTHERN RESEARCH INSTITUTE (US) 1993-02-03 EP claimed
US-5128458-A 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents SOUTHERN RESEARCH INSTITUTE (US) 1992-07-07 US claimed
WO-1992001700-A1 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) 1992-02-06 WO claimed
WO-1991016333-A1 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS SOUTHERN RESEARCH INSTITUTE (US) 1991-10-31 WO claimed